Morteau, France

Jean M Rognon


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1997

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Jean M Rognon: Pioneering Compounds for Medical Applications

Introduction: Jean M Rognon, based in Morteau, France, is an inventive mind known for his significant contributions to the realm of medicinal chemistry. As an inventor with one patent to his name, Rognon has focused on developing innovative compounds that hold potential therapeutic benefits.

Latest Patents: Rognon's patent, titled "15-deoxyspergualin analogs, their method of preparation and their use," indicates a notable exploration into compounds structurally related to 15-deoxyspergualin. The patent outlines a series of compounds characterized by a specific formula, with variations primarily involving the chemical groups attached to a central structure. This innovative work adds to the growing field of medicinal compounds aimed at improving treatment options.

Career Highlights: Jean M Rognon has made strides in the field by working with renowned companies, such as Fournier Industrie Et Santé. His experience and expertise in chemical compounds have enabled him to innovate solutions that have the potential to impact various medical applications significantly.

Collaborations: Throughout his career, Rognon has worked alongside talented colleagues, including Patrice Renaut and Luc Lebreton. These collaborations highlight the importance of teamwork in scientific innovation and underscore the collective effort required to bring new inventions to fruition.

Conclusion: Jean M Rognon stands out as an inventor dedicated to advancing medicinal chemistry through innovative approaches. His patent focusing on 15-deoxyspergualin analogs exemplifies a commitment to creating novel therapeutic solutions. As Rognon continues his work, he undoubtedly paves the way for future discoveries that may benefit the medical community and patients alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…